Search Results - "Mack, Frederic"

Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial by Weller, Johannes, MD, Tzaridis, Theophilos, MD, Mack, Frederic, MD, Steinbach, Joachim Peter, Prof, Schlegel, Uwe, Prof, Hau, Peter, Prof, Krex, Dietmar, MD, Grauer, Oliver, MD, Goldbrunner, Roland, Prof, Bähr, Oliver, MD, Uhl, Martin, MD, Seidel, Clemens, MD, Tabatabai, Ghazaleh, Prof, Brehmer, Stefanie, MD, Bullinger, Lars, Prof, Galldiks, Norbert, MD, Schaub, Christina, MD, Kebir, Sied, MD, Stummer, Walter, Prof, Simon, Matthias, MD, Fimmers, Rolf, PhD, Coch, Christoph, MD, Glas, Martin, MD, Herrlinger, Ulrich, Prof, Schäfer, Niklas, MD

“…SummaryBackgroundThe CeTeG/NOA-09 trial showed significantly longer overall survival with combined lomustine–temozolomide therapy compared with standard…”
Get full text

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma by Schaub, Christina, Schäfer, Niklas, Mack, Frederic, Stuplich, Moritz, Kebir, Sied, Niessen, Michael, Tzaridis, Theophilos, Banat, Mohammed, Vatter, Hartmut, Waha, Andreas, Herrlinger, Ulrich, Glas, Martin

“…Purpose The adequate second-line therapy of patients with glioblastoma (GBM) is a matter of ongoing debate. This particularly applies to patients with a…”
Get full text

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial by Schaub, Christina, Kebir, Sied, Junold, Nina, Hattingen, Elke, Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Bähr, Oliver, Kortmann, Rolf-Dieter, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Braun, Christian, Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Herrlinger, Ulrich, Glas, Martin

“…Background We evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in…”
Get full text

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial by Herrlinger, Ulrich, Schäfer, Niklas, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Maciaczyk, Jaroslaw, Grau, Stefan, Schnell, Oliver, Hänel, Mathias, Krex, Dietmar, Vajkoczy, Peter, Gerlach, Rüdiger, Kortmann, Rolf-Dieter, Mehdorn, Maximilian, Tüttenberg, Jochen, Mayer-Steinacker, Regine, Fietkau, Rainer, Brehmer, Stefanie, Mack, Frederic, Stuplich, Moritz, Kebir, Sied, Kohnen, Ralf, Dunkl, Elmar, Leutgeb, Barbara, Proescholdt, Martin, Pietsch, Torsten, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin

“…In patients with newly diagnosed glioblastoma that harbors a nonmethylated O(6)-methylguanine-DNA methyltransferase promotor, standard temozolomide (TMZ) has,…”
Get full text

Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy by Kebir, Sied, Kuchelmeister, Klaus, Niehusmann, Pitt, Nelles, Michael, Kim, Young, Thanendrarajan, Sharmilan, Schäfer, Niklas, Stuplich, Moritz, Mack, Frederic, Scheffler, Björn, Urbach, Horst, Glas, Martin, Herrlinger, Ulrich

“…Intravascular diffuse large B-cell lymphoma limited to the CNS (cIVL) is a very rare malignant disorder characterized by a selective accumulation of neoplastic…”
Get full text

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial by Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter, Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh, Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert, Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schäfer, Niklas, Kebir, Sied, Weller, Johannes, Schaub, Christina, Stummer, Walter, Tonn, Jörg-Christian, Simon, Matthias, Keil, Vera C, Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang, Weller, Michael, Fimmers, Rolf, Schmid, Matthias, Hattingen, Elke, Pietsch, Torsten, Coch, Christoph, Glas, Martin

“…There is an urgent need for more effective therapies for glioblastoma. Data from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide…”
Get full text

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET by Kebir, Sied, Fimmers, Rolf, Galldiks, Norbert, Schäfer, Niklas, Mack, Frederic, Schaub, Christina, Stuplich, Moritz, Niessen, Michael, Tzaridis, Theophilos, Simon, Matthias, Stoffels, Gabriele, Langen, Karl-Josef, Scheffler, Björn, Glas, Martin, Herrlinger, Ulrich

“…Pseudoprogression (PsP) is characterized by therapy-associated but not tumor growth-associated increases of contrast-enhancing glioblastoma lesions on MRI…”
Get full text

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O 6 -Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial by Herrlinger, Ulrich, Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W., Uhl, Martin, Maciaczyk, Jaroslaw, Grau, Stefan, Schnell, Oliver, Hänel, Mathias, Krex, Dietmar, Vajkoczy, Peter, Gerlach, Rüdiger, Kortmann, Rolf-Dieter, Mehdorn, Maximilian, Tüttenberg, Jochen, Mayer-Steinacker, Regine, Fietkau, Rainer, Brehmer, Stefanie, Mack, Frederic, Stuplich, Moritz, Kebir, Sied, Kohnen, Ralf, Dunkl, Elmar, Leutgeb, Barbara, Proescholdt, Martin, Pietsch, Torsten, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin

“…Purpose In patients with newly diagnosed glioblastoma that harbors a nonmethylated O 6 -methylguanine–DNA methyltransferase promotor, standard temozolomide…”
Get full text

Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide by Stuplich, Moritz, Hadizadeh, Dariusch R, Kuchelmeister, Klaus, Scorzin, Jasmin, Filss, Christian, Langen, Karl-Josef, Schäfer, Niklas, Mack, Frederic, Schüller, Heinrich, Simon, Matthias, Glas, Martin, Pietsch, Torsten, Urbach, Horst, Herrlinger, Ulrich

Get full text

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab by Schaub, Christina, Tichy, Julia, Schäfer, Niklas, Franz, Kea, Mack, Frederic, Mittelbronn, Michel, Kebir, Sied, Thiepold, Anna-Luisa, Waha, Andreas, Filmann, Natalie, Banat, Mohammed, Fimmers, Rolf, Steinbach, Joachim P., Herrlinger, Ulrich, Rieger, Johannes, Glas, Martin, Bähr, Oliver

“…The value of bevacizumab (BEV) in recurrent glioblastoma is unclear. Imaging parameters and progression-free survival (PFS) are problematic endpoints. Few data…”
Get full text

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma by Schäfer, Niklas, Gielen, Gerrit H., Kebir, Sied, Wieland, Anja, Till, Andreas, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Reinartz, Roman, Niessen, Michael, Fimmers, Rolf, Simon, Matthias, Coch, Christoph, Fuhrmann, Christine, Herrlinger, Ulrich, Scheffler, Björn, Glas, Martin

“…Purpose Dovitinib (TKI258) is an oral multi-tyrosine kinase inhibitor of FGFR, VEGFR, PDGFR β, and c-Kit. Since dovitinib is able to cross the blood–brain…”
Get full text

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma by Schäfer, Niklas, Proescholdt, Martin, Steinbach, Joachim P, Weyerbrock, Astrid, Hau, Peter, Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W, Uhl, Martin, Grau, Stefan, Hänel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos, Nießen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin, Herrlinger, Ulrich

“…The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of…”
Get full text

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial by Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke, Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert, Weller, Johannes, Mack, Frederic, Tzaridis, Theophilos, Bähr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh, Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin, Herrlinger, Ulrich

“…Purpose The phase II GLARIUS trial assigned patients with newly diagnosed, O -6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to…”
Get full text

Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma by Mack, Frederic, Schäfer, Niklas, Kebir, Sied, Stuplich, Moritz, Schaub, Christina, Niessen, Michael, Scheffler, Björn, Herrlinger, Ulrich, Glas, Martin

“…After the failure of radiotherapy and temozolomide, there is no established standard therapy for patients with recurrent glioblastoma (GBM). Based on the…”
Get more information

ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial by Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim, Schlegel, Uwe, Sabel, Michael, Hau, Peter, Kortman, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Tabatabai, Ghazaleh, Ringel, Florian, Schmidt-Graf, Friederike, Brehmer, Stefanie, Weyerbrock, Astrid, Bullinger, Lars, Vajkoczy, Peter, Vatter, Hartmut, Schäfer, Niklas, Kebir, Sied, Weller, Johannes, Stummer, Walter, Simon, Matthias, Keil, Vera, Nelles, Michael, Fimmers, Rolf, Pietsch, Torsten, Hattingen, Elke, Coch, Christoph, Glas, Martin

“…There is an urgent need for more effective therapies in glioblastoma (GBM). Data from the single arm UKT-03 trial (Glas et al., J Clin Oncol 27, 1257,…”
Get full text

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival by Schaub, Christina, Greschus, Susanne, Seifert, Mirko, Waha, Andreas, Blasius, Elias, Rasch, Katja, Landwehr, Christiane, Mack, Frederic, Schäfer, Niklas, Stuplich, Moritz, Kebir, Sied, Vilz, Belinda, Scheffler, Björn, Boström, Jan, Simon, Matthias, Urbach, Horst, Glas, Martin, Herrlinger, Ulrich

“…In this study, we analyzed the prognostic value of different MRI progression patterns for survival in patients with recurrent malignant glioma treated with the…”
Get more information

NIMG-40MRI TUMOR PROGRESSION PATTERNS IN THE GLARIUS TRIAL by Kebir, Sied, Schaub, Christina, Hattingen, Elke, Junold, Nina, Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Bähr, Oliver, Proescholdt, Martin, Glas, Martin, Herrlinger, Ulrich

Get full text

NIMG-41MRI FINDINGS IN THE GLARIUS TRIAL: PROGNOSTIC AND PREDICTIVE IMPLICATIONS by Kebir, Sied, Schaub, Christina, Hattingen, Elke, Junold, Nina, Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Bähr, Oliver, Proescholdt, Martin, Glas, Martin, Herrlinger, Ulrich

Get full text

F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report by Niessen, Michael, Bundschuh, Ralph, Esslerm, Markus, Greschus, Susanne, Schaub, Christina, Mueller, Marcus, Glas, Martin, Stuplich, Moritz, Herrlinger, Ulrich, Nelles, Michael, Gaertner, Florian C, Schafer, Niklas, Simon, Matthias, Kebir, Sied, Mack, Frederic

Get full text

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report by KEBIR, SIED, GAERTNER, FLORIAN C, MUELLER, MARCUS, NELLES, MICHAEL, SIMON, MATTHIAS, SCHÄFER, NIKLAS, STUPLICH, MORITZ, SCHAUB, CHRISTINA, NIESSEN, MICHAEL, MACK, FREDERIC, BUNDSCHUH, RALPH, GRESCHUS, SUSANNE, ESSLER, MARKUS, GLAS, MARTIN, HERRLINGER, ULRICH

“…Large demyelinating inflammatory central nervous system (CNS) lesions may present with contrast enhancement on magnetic resonance imaging and may mimic CNS…”
Get full text